NEOS Neos Therapeutics Inc.

1.39
-0.03  -2%
Previous Close 1.42
Open 1.43
Price To Book -46.33
Market Cap 69,125,082
Shares 49,730,275
Volume 156,997
Short Ratio
Av. Daily Volume 182,646
Stock charts supplied by TradingView

NewsSee all news

  1. Neos Therapeutics to Present at Cantor Fitzgerald Global Healthcare Conference

    DALLAS and FORT WORTH, Texas, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a commercial-stage pharmaceutical company utilizing its novel microparticle delivery technology to develop and

  2. Neos Therapeutics to Present at Two Upcoming September Conferences

    DALLAS and FORT WORTH, Texas, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a commercial-stage pharmaceutical company utilizing its novel microparticle delivery technology to develop and

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approval announced September 15, 2017.
NT-0201
Attention deficit hyperactivity disorder (ADHD)
Approved January 27, 2016.
Adzenys XR-ODT
Attention deficit hyperactivity disorder (ADHD)
Approval announced June 19, 2017.
Cotempla XR-ODT
Attention deficit hyperactivity disorder (ADHD)
Phase 1 trial to commence 1H 2020.
NT0502
Sialorrhea

Latest News

  1. Neos Therapeutics to Present at Cantor Fitzgerald Global Healthcare Conference

    DALLAS and FORT WORTH, Texas, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a commercial-stage pharmaceutical company utilizing its novel microparticle delivery technology to develop and

  2. Neos Therapeutics to Present at Two Upcoming September Conferences

    DALLAS and FORT WORTH, Texas, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a commercial-stage pharmaceutical company utilizing its novel microparticle delivery technology to develop and